Precision’s Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series.

“Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types.” (subscription required):

(more…)

As clinical trial protocols have become more complex in recent years, institutions are facing new challenges in keeping up with the advancements. In this Q&A, Precision’s Sofia Baig, President of Clinical Solutions, discusses the challenges these institutions are facing, how sites can keep pace with new technologies, and improving efficiency in early and later phase research.

(more…)

The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside. Precision’s Deb Phippard surveys the landscape in MedCity News.

(more…)

Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.

(more…)